Myriad Genetics MYGN Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70%0.0pp | 69.9%0.0pp | 70.4%+1.2pp | 70.4%+1.4pp | 70%+1.2pp | |
| Operating margin | -46.9%-31.9pp | -47%-32.2pp | -51%-36.9pp | -50.1%-30.7pp | -15%+15.1pp | |
| Net margin | -48.2%-36.0pp | -44.4%-29.2pp | -48.5%-34.4pp | -47.4%-28.1pp | -12.2%+18.1pp | |
| Returns | ||||||
| Return on equity | -76.7%-62.9pp | -68.5%-51.3pp | -72.5%-56.1pp | -70%-49.0pp | -13.8%+15.6pp | |
| Return on invested capital | -65.7%-49.7pp | -67%-50.8pp | -70.4%-55.6pp | -67.2%-47.8pp | -15.9%+10.9pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.2× | 1×+0.2× | 0.9×+0.2× | 0.9×+0.2× | 0.8×+0.1× | |
| Liquidity | ||||||
| Current ratio | 2.4×+0.5× | 2.5×+0.7× | 2.3×+0.4× | 1.4×-0.5× | 1.9×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.4× | 0.6×+0.4× | 0.6×+0.4× | 0.4×+0.2× | 0.2×0.0× | |
| Per Share | ||||||
| Book value per share | $3.60-53.3% | $3.97-48.6% | $4.00-50.3% | $4.20-48.7% | $7.71-8.8% | |
| Valuation | ||||||
| Market capitalization | $512.85M+13.1% | $573.26M-54.1% | $672.71M-70.0% | $465.5M-76.7% | $809.91M-53.5% | |
| Price / sales | 0.6×+0.1× | 0.7×-0.8× | 0.8×-1.9× | 0.6×-1.9× | 1×-1.3× | |
| Price / book | 1.5×+0.9× | 1.6×-0.2× | 1.8×-1.3× | 1.2×-1.5× | 1.1×-1.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Myriad Genetics's profit margins?
- Myriad Genetics (MYGN) runs a 70.0% gross margin and a -46.9% operating margin, with a -48.2% net margin.
- Where do Myriad Genetics's ratios come from?
- Every ratio is computed from Myriad Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
